Leukemia, Myeloid: all 2,432 studies
Page 1 of 25. Open to participants first (205), then studies with results posted, then the rest; newest registration first within each.
- Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT07668557Phase 1
- Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AMLNot yet recruitingNCT07604233Phase 1/2
- Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid LeukemiaRecruitingNCT07439211Phase 1
- Halt Aging in Survivors of Blood CancersRecruitingNCT07292272Not applicable
- Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AMLNot yet recruitingNCT07157514Phase 2/3
- A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid LeukemiaRecruitingNCT07028073Phase 1/2
- a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid LeukemiaRecruitingNCT07007949Phase 2
- XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid LeukemiaRecruitingNCT06980155Early Phase 1
- The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic TumorsRecruitingNCT06911710Phase 1/2
- Gut Health in Children With CancerRecruitingNCT06899581
- Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical TransplantationRecruitingNCT06892223Phase 2
- Infusion of Alloreactive nk Cells for Mrd-positive Aml PatientsRecruitingNCT06885476Not applicable
- A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT06880354Phase 1
- A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AMLRecruitingNCT06879847Not applicable
- Targeting Acute Myeloid Leukemia Immunosuppressive Microenvironment by combinedIDO1 Inhibition and PD-1 BlockadeRecruitingNCT06874257
- Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid LeukemiaRecruitingNCT06869265Phase 2
- Evaluation of CD47, "Do Not Eat Me" Signal Expression in Chronic Myeloid LeukemiaNot yet recruitingNCT06865443
- Effectiveness of Early Intervention in Palliative Care for Acute Myeloid Leukemia Patients Comparing to Standard of CareNot yet recruitingNCT06848270Not applicable
- CD123-CD16-NK Cells Immunotherapy for AMLRecruitingNCT06835140Phase 1
- Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AMLRecruitingNCT06827899Phase 2
- HVA vs IA/DA or VA in the Treatment of ND HR-AMLRecruitingNCT06810791Phase 3
- Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid LeukemiaRecruitingNCT06802718Phase 3
- Epidemiology of Infection in Acute Myeloid Leukemia (AML)Not yet recruitingNCT06797648
- Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia.Not yet recruitingNCT06786299Early Phase 1
- Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP InhibitorsRecruitingNCT06785077Not applicable
- Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCTRecruitingNCT06783790Phase 2
- NK Cell Infusion for Remission Consolidation in AML: A Phase II TrialNot yet recruitingNCT06783478Phase 2
- Oral-ATO for TP53-mutated Myeloid MalignanciesRecruitingNCT06778187Phase 2
- Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic TreatmentsRecruitingNCT06764459
- A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT06762132Early Phase 1
- Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT06760260Early Phase 1
- Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention.Not yet recruitingNCT06754540Phase 2
- BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid LeukemiaRecruitingNCT06746519Phase 1/2
- Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AMLRecruitingNCT06741722Phase 2
- Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AMLRecruitingNCT06737523Phase 1
- Interaction Between Gut Microbiota and TKIs in Defining the Clinical Outcomes of Patients With CMLRecruitingNCT06724536
- Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous LeukemiaNot yet recruitingNCT06702098Early Phase 1
- Daunorubicin + Cytarabine + Venetoclax in de Novo AMLEnrolling by invitationNCT06697327Not applicable
- Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive TreatmentRecruitingNCT06696183Phase 2
- A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive LeukemiaNot yet recruitingNCT06672263Phase 1
- Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid LeukemiaNot yet recruitingNCT06667973Phase 2
- Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid LeukemiaNot yet recruitingNCT06652685Phase 2
- Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML PatientsRecruitingNCT06651866Phase 1
- Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT TrialEnrolling by invitationNCT06646978
- Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction TherapyRecruitingNCT06643962Not applicable
- Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid LeukemiaNot yet recruitingNCT06643195Not applicable
- EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid LeukemiaRecruitingNCT06642025Early Phase 1
- APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AMLRecruitingNCT06634394Phase 1
- Twice-per-weekSelinexor, 2 Days MelphalanNot yet recruitingNCT06613035Phase 3
- TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia.Not yet recruitingNCT06602323Phase 2
- TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid LeukemiaNot yet recruitingNCT06598969Phase 2
- VA as Maintenance Therapy Post Allo-HSCT in MDS and AMLNot yet recruitingNCT06598384Phase 2
- RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CRRecruitingNCT06571825Phase 4
- Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute LeukemiaNot yet recruitingNCT06559644Early Phase 1
- Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid LeukemiaRecruitingNCT06537843Phase 2
- Breath Analysis for the Detection of Invasive Fungal InfectionsRecruitingNCT06537726
- VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDSRecruitingNCT06536959Phase 2
- Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AMLRecruitingNCT06536010Not applicable
- Sorafenib Relapase Prophylaxis After HCT With PTBCy RegimenRecruitingNCT06532084Phase 2
- Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT06532058Phase 2
- Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)Not yet recruitingNCT06530810Phase 1
- ELN 2022 in MENAFC ( Middle Eastern or North Coast of Africa ) Patients With Newly AMLNot yet recruitingNCT06512610
- Vitamin A and D Supplementation in Allogeneic HCTRecruitingNCT06508099Phase 2
- A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic SyndromeRecruitingNCT06501196Phase 1
- CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AMLNot yet recruitingNCT06470841Phase 2
- ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AMLNot yet recruitingNCT06463327Phase 1
- VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCTRecruitingNCT06447090Phase 2
- A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After TransplantationNot yet recruitingNCT06441084Phase 1
- Mitoxantrone for Venetoclax Resistant Acute Myeloid LeukemiaRecruitingNCT06429449Phase 1
- Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AMLRecruitingNCT06420063Phase 1/2
- IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AMLRecruitingNCT06418776Phase 3
- Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML PatientsRecruitingNCT06394011Phase 2
- The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBPRecruitingNCT06390306
- A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid LeukemiaNot yet recruitingNCT06387420Phase 1/2
- Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AMLNot yet recruitingNCT06385808Not applicable
- Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) TrialRecruitingNCT06355583Phase 2
- BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in ChildrenNot yet recruitingNCT06347458Phase 1
- MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)RecruitingNCT06345365Phase 3
- A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AMLRecruitingNCT06329999Not applicable
- Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.RecruitingNCT06328179Not applicable
- Interest of Light Therapy in Hematology - The PHOTO-TREAT StudyRecruitingNCT06326268Not applicable
- Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT MutationRecruitingNCT06316960Phase 2
- MRD Response-adapted Allo-HSCT for Adverse-risk AMLRecruitingNCT06301425Not applicable
- The Evaluation and Comparison of BCR-ABL p210 mRNA Transcripts (%IS Unit) Results Between Dr. PCR™ BCR-ABL1 Major IS Detection Kit (Optolane) and QXDx™ BCR-ABL %IS Kit (Bio-Rad) in Chronic Myeloid Leukemia PatientsRecruitingNCT06301321
- Study of REM-422 in Patients With AML or Higher Risk MDSRecruitingNCT06297941Phase 1
- Personalized Medication Software for BCL-2 Inhibitor in AML Patients Using Machine Learning and GenomicsNot yet recruitingNCT06295029
- Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia PatientsNot yet recruitingNCT06252584Phase 1
- UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid LeukemiaRecruitingNCT06245746Phase 1
- A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid LeukemiaRecruitingNCT06235801Phase 1/2
- Individualized Treatment of Pediatric R/R AML Based on Transcriptomic Profile and in Vitro Drug Sensitivity TestRecruitingNCT06233526Not applicable
- Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AMLRecruitingNCT06232694Not applicable
- Dynamics of Resistance Emergence to Azacitidine-based Therapies in Acute Myeloid LeukemiaRecruitingNCT06225128
- Off-the-shelf CD123 CAR-NK for R/R AMLRecruitingNCT06201247Early Phase 1
- A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid LeukemiaNot yet recruitingNCT06182592Phase 3
- Role of BMP Pathway in MDS ProgressionNot yet recruitingNCT06175923
- Venetoclax in Combination With Standard Induction and Consolidation Chemotherapy in Newly Diagnosed Young AML PatientsEnrolling by invitationNCT06162325
- CIML NK Cells With Venetoclax for AMLRecruitingNCT06152809Phase 1
- Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell TransplantationRecruitingNCT06138587Phase 1
- Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted TherapyRecruitingNCT06130787Not applicable
- Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)RecruitingNCT06125652Phase 1/2